Medical Devices
HeartBeam Announces Public Offering to Fund Cardiac Technology Commercialization and AI Development
HeartBeam Inc. is launching a public offering to finance the commercialization of its FDA-cleared 12-lead ECG system and advance AI initiatives for cardiac care.
Polyrizon Secures $3.5 Million in Funding to Advance Intranasal Protective Technology
Polyrizon Ltd. has raised $3.5 million through a registered direct offering and private placement to fund development of its nasal spray hydrogel technology designed to create protective barriers against viruses and allergens.
Compact Proton Therapy Systems Promise Greater Accessibility for Cancer Patients
Innovative compact proton therapy systems are reducing equipment size and costs, potentially making this precise cancer treatment more accessible to patients who previously couldn't access it due to traditional systems' limitations.
Nutriband CEO Discusses AVERSA Technology's Role in Addressing Opioid Crisis on Podcast
Nutriband Inc. CEO Gareth Sheridan highlighted the company's AVERSA abuse-deterrent transdermal technology on a podcast, emphasizing its potential to reduce misuse of high-risk drugs like fentanyl while maintaining patient access.
BioElectronics Expands ActiPatch to Taiwan Through Aphrodite Medical Group Partnership
BioElectronics Corporation's expansion of its FDA-cleared ActiPatch device to Taiwan through distributor Aphrodite Medical Group represents a significant shift toward drug-free pain management alternatives in Asian healthcare markets.
Aclarion Authorizes $2.5 Million Stock Buyback, Signaling Confidence in Nociscan Growth
Aclarion's board-approved share repurchase program highlights the company's disciplined capital management and belief that its stock is undervalued despite the ongoing clinical adoption of its Nociscan platform for chronic back pain diagnosis.
Nephros Targets $25 Million Opportunity in Greater New York with New Regional Sales Leader
Nephros appoints Dana Cunningham as dedicated regional sales leader to accelerate growth in the Greater New York market, which it estimates represents a $25 million annual addressable opportunity for point-of-use filtration and services.
HeartBeam Closes $10 Million Public Offering to Accelerate Cardiac Tech Commercialization
HeartBeam Inc. raised $10 million in a public offering to fund the commercialization of its FDA-cleared 12-lead synthesized ECG system and other cardiac technologies.
HeartBeam Closes $10M Public Offering to Fund Commercialization of ECG Technology
HeartBeam raised $10 million in a public offering to advance its FDA-cleared 12-lead synthesized ECG system and heart attack detection technologies, positioning the company for expanded market reach.
Ocumetics Reports Life-Changing Six-Month Results from First-in-Human Study of Accommodating Intraocular Lens
Ocumetics Technology Corp. announced that six-month postoperative results from its first-in-human study of the Ocumetics Accommodating Intraocular Lens show continued vision improvements and meaningful quality-of-life enhancements for patients, with plans to advance to Group Two surgeries.
BioXgen Seeks Crowdfunding Investment for Cardiac Patch Targeting Post-Surgery Complication
BioXgen is launching a Regulation Crowdfunding investment round and hosting a webinar to demonstrate its cardiac patch designed to prevent postoperative atrial fibrillation, a common complication affecting nearly half of open-heart surgery patients.
HeartBeam Ranked Second Globally in Portable ECG Innovation
HeartBeam has been recognized as a top global innovator in portable ECG technology, ranking second worldwide in 12-lead ECG innovation among 243 companies analyzed, highlighting the company's growing influence in remote cardiac care solutions.
HeartBeam Ranked Second Globally in 12-Lead ECG Innovation by PatentVest Report
HeartBeam Inc. has been recognized as a top global innovator in portable ECG technology, ranking second worldwide in 12-lead ECG innovation among 243 companies evaluated, highlighting the company's growing influence in remote cardiac care technology.
HOPE Therapeutics Launches Revolutionary One-Day Depression Treatment Protocol in Florida
NRx Pharmaceuticals' subsidiary HOPE Therapeutics has initiated Florida's first deployment of a rapid one-day TMS protocol for treatment-resistant depression, potentially transforming care for millions suffering from depression and PTSD.
Houston Medical Technology Company Wins Global Health Tech Competition for Pediatric Heart Innovation
PolyVascular's victory in the American Heart Association's Health Tech Competition highlights a breakthrough minimally invasive valve technology that could transform care for children with congenital heart disease by reducing the need for repeated open-heart surgeries.
Wireless Brain Implants Could Revolutionize Neurological Treatment Without Surgery
MIT researchers have developed microscopic wireless implants that can navigate to brain tissue autonomously, potentially eliminating the need for surgery in treating tumors and neurological conditions.
Olympus Announces Major Restructuring Strategy to Transform Endoscopy Care Through AI and Robotics
Olympus Corporation unveiled a comprehensive corporate strategy focused on advancing AI-powered endoscopy and robotics while implementing significant workforce reductions and organizational changes to drive innovation in medical technology.
HeartBeam Submits Breakthrough ECG Technology for FDA Clearance
HeartBeam Inc. has submitted its innovative 12-lead ECG synthesis software to the FDA for clearance, representing a significant advancement in cardiac arrhythmia detection and management.
Sigyn Therapeutics Advances CardioDialysis™ to Address Cardiovascular Disease in Dialysis Patients
Sigyn Therapeutics is developing CardioDialysis™, a medical device that leverages existing dialysis infrastructure to treat cardiovascular disease in end-stage renal disease patients, who face a 67% mortality rate from heart conditions and limited benefit from traditional drug therapies.
HeartBeam Receives Buy Rating and $4 Price Target from Roth Capital, Highlighting FDA Clearance Catalyst
HeartBeam Inc. received a Buy rating and $4 price target from Roth Capital, which emphasized the company's potential FDA clearance for its 12-lead ECG synthesis software and its position to transform remote cardiac monitoring.
Ocumetics Reports Promising Early Results in First Human Lens Implant Study
Ocumetics Technology Corp. announced encouraging one-month vision results from its first human clinical study of an accommodating intraocular lens, showing potential to transform cataract treatment and reduce dependence on corrective lenses.
NeuroOne Granted 180-Day Extension to Regain Nasdaq Compliance
NeuroOne Medical Technologies has received an additional 180 days to meet Nasdaq's minimum bid price requirement, providing crucial breathing room for the neurological device company to stabilize its stock performance and avoid potential delisting.
LogicMark CEO Discusses Connected Care Platform for At-Risk Populations
LogicMark CEO Chia-Lin Simmons detailed the company's comprehensive medical safety device offerings for seniors across all care levels during a recent interview, highlighting the importance of connected care technology for vulnerable populations.
AI Tool Detects Structural Heart Disease Using Smartwatch ECG Sensors
An artificial intelligence algorithm paired with smartwatch ECG sensors can accurately detect structural heart diseases, potentially making early screening more accessible to millions of people who already own these devices.
HeartBeam to Discuss Q3 2025 Results and Regulatory Progress in November Conference Call
HeartBeam will host a conference call on November 13, 2025, to discuss third-quarter results and provide updates on its FDA-cleared 3D ECG technology that could transform remote cardiac monitoring.
Olympus Launches Combined Imaging Mode to Enhance Cancer Detection Capabilities
Olympus Corporation has introduced a new NBI+TXI observation mode for its EVIS X1 endoscopy system that combines two advanced imaging technologies to improve detection and diagnostic accuracy for gastrointestinal and respiratory cancers, addressing Japan's high cancer incidence rates.
FDA Clears First 4-in-1 Home Test for RSV, Flu, and COVID Detection
ACON Laboratories has received FDA clearance for the first over-the-counter home test that simultaneously detects RSV, influenza A, influenza B, and COVID-19, representing a significant advancement in consumer respiratory health monitoring.
PetVivo Holdings to Showcase Veterinary Medical Innovations at Spartan Capital Investor Conference
PetVivo Holdings will present its innovative veterinary medical devices at the Spartan Capital Securities investor conference, highlighting the company's growth potential in the animal healthcare market.
New LED Therapy Shows Promise in Targeting Cancer Cells While Preserving Healthy Tissues
Researchers have developed a novel LED-based cancer treatment that selectively destroys cancer cells while minimizing damage to healthy tissues, potentially offering a more precise alternative to conventional therapies like chemotherapy and radiation.
Nutriband's AVERSA Fentanyl Patch Advances Toward 2026 FDA Submission with $200M Market Potential
Nutriband Inc. is progressing with its abuse-deterrent fentanyl patch technology that could generate up to $800 million in annual sales while addressing the opioid crisis through tamper-resistant transdermal delivery.